Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply BioSpaceThe investment will expand Resilience's U.S.Metabolic & GLP-1Read full story pharminent July 31, 2026 (Last updated: August 3, 2026) BioSpace The investment will expand Resilience’s U.S. Metabolic & GLP-1 Read full story Post navigation Previous: Novo setback casts doubt on a new way to treat heart diseaseNext: Novo Nordisk’s Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular Trial Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026